<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03160638</url>
  </required_header>
  <id_info>
    <org_study_id>AZT_DSTB_BB</org_study_id>
    <nct_id>NCT03160638</nct_id>
  </id_info>
  <brief_title>Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis</brief_title>
  <official_title>A Prospective, Randomized Pilot Study of the Immunomodulatory Effects of Azithromycin in Adults With Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:&#xD;
&#xD;
      Treatment in tuberculosis (TB) is focused on eradication of the bacterial infection, however,&#xD;
      after treatment approximately half of patients are left with a significant and permanent&#xD;
      respiratory impairment. Adjunctive host-directed therapies are being investigated to modulate&#xD;
      host immune responses to target mycobacterium tuberculosis (Mtb) infection and/or reduce&#xD;
      excessive inflammation, prevent pathological tissue damage, preserve lung function and&#xD;
      enhance effectiveness of standard drug therapy, while nonetheless eliminating Mtb. Macrolide&#xD;
      antibiotics have previously been used in the treatment of multidrug-resistant TB. In addition&#xD;
      to their antibiotic effects, macrolides have also been recognized to induce anti-inflammatory&#xD;
      and immunomodulatory effects in other lung diseases.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To investigate the immunomodulatory effects of azithromycin in tuberculosis patients&#xD;
      receiving standard therapy (isoniazid, rifampicin, pyrazinamide, ethambutol (HRZE))&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      A prospective, randomized open label intervention trial to investigate the immunomodulatory&#xD;
      effects of azithromycin&#xD;
&#xD;
      Study population: 24&#xD;
&#xD;
      Intervention: azithromycin 250 mg once daily or standard of care (control)&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
        1. To assess whether azithromycin enhances resolution of systemic inflammation in patients&#xD;
           with drug susceptible pulmonary TB receiving standard treatment.&#xD;
&#xD;
        2. To assess whether azithromycin on top of standard treatment in patients with drug&#xD;
           susceptible pulmonary TB reduces airway inflammation and reduces tissue degradation and&#xD;
           remodeling&#xD;
&#xD;
        3. To investigate whether these effects are associated within shortening of the time to&#xD;
           sputum conversion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic inflammation</measure>
    <time_frame>Before randomization, day 7 and day 28</time_frame>
    <description>Changes in total &amp; differential white blood cell counts markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic inflammation</measure>
    <time_frame>Before randomization, day 7 and day 28</time_frame>
    <description>Changes in serum inflammatory markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary inflammation</measure>
    <time_frame>Before randomization and day 28</time_frame>
    <description>Changes in total and differential sputum inflammatory cell counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary inflammation</measure>
    <time_frame>Before randomization and day 28</time_frame>
    <description>Changes in cytokine levels in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary tissue degradation</measure>
    <time_frame>Before randomization and day 28</time_frame>
    <description>Changes in markers of tissue degradation in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary tissue degradation</measure>
    <time_frame>Before randomization, day 7 and day 28</time_frame>
    <description>Changes in markers of tissue degradation in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary tissue remodeling</measure>
    <time_frame>Before randomization and day 28</time_frame>
    <description>Changes in markers of tissue remodeling in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary tissue remodeling</measure>
    <time_frame>Before randomization, day 7 and day 28</time_frame>
    <description>Changes in markers of tissue remodeling in serum</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of HRZE treatment outcomes</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Time to sputum conversion</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of HRZE treatment outcomes</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Drug exposure of HRZE in relation to minimal inhibitory concentration (MIC) of Mtb for HRZE</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug exposure of azithromycin</measure>
    <time_frame>Day 7</time_frame>
    <description>AUC0-24h of azithromycin in TB</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug exposure of azithromycin</measure>
    <time_frame>Day 7</time_frame>
    <description>Metabolic clearance (CLm) of azithromycin in TB</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug exposure of azithromycin</measure>
    <time_frame>Day 7</time_frame>
    <description>Volume of distribution (V) of azithromycin in TB</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug exposure of azithromycin</measure>
    <time_frame>Day 7</time_frame>
    <description>Elimination half-life (T1/2) of azithromycin in TB</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Azithromycin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will be treated with azithromycin 250 mg once daily on top of standard HRZE treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm will receive no additional treatment on top of standard HRZE treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 250 mg</intervention_name>
    <description>Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1</description>
    <arm_group_label>Azithromycin arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of drug sensitive pulmonary tuberculosis (molecular test;&#xD;
             identification Mtb complex; absence of resistance genes such as rpob, inha, katg)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient reported previous history of treatment for tuberculosis&#xD;
&#xD;
          -  Patients younger than 18 years&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Patients with hypersensitivity to macrolide antibiotics&#xD;
&#xD;
          -  Treatment with any macrolide in the previous month&#xD;
&#xD;
          -  Treatment with any tetracycline in the previous month&#xD;
&#xD;
          -  Treatment with any inhaled or oral corticosteroid in the previous month&#xD;
&#xD;
          -  Concomitant treatment with analgesic (NSAIDs)/immunosuppressant drugs (except&#xD;
             paracetamol).&#xD;
&#xD;
          -  Treatment with digoxin&#xD;
&#xD;
          -  Patients with gastrointestinal complaints, like diarrhea and vomiting (≥grade 2,&#xD;
             observed)&#xD;
&#xD;
          -  Other known respiratory diseases, including bronchiectasis, pulmonary fibrosis,&#xD;
             pulmonary vascular disease or lung cancer&#xD;
&#xD;
          -  HIV-1 infection or AIDS&#xD;
&#xD;
          -  Impaired liver function (Child-Pugh score C)&#xD;
&#xD;
          -  Patients with a known QTc ≥500 ms. An electrocardiogram (ECG) will be recorded.&#xD;
&#xD;
          -  Inability to spontaneously produce sputum upon diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bart Dekkers, PharmD, PhD</last_name>
    <phone>+31506314070</phone>
    <email>b.g.j.dekkers@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
    <phone>+31506314070</phone>
    <email>j.w.c.alffenaar@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart GJ Dekkers, PharmD, PhD</last_name>
      <phone>+315014071</phone>
      <email>b.g.j.dekkers@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jan-Willem C Alffenaar, PharmD, PhD</last_name>
      <phone>+315014071</phone>
      <email>j.w.c.alffenaar@umcg.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Jan-Willem C Alffenaar</investigator_full_name>
    <investigator_title>Principal Investigator, PharmD, PhD</investigator_title>
  </responsible_party>
  <keyword>Azithromycin</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Tissue degradation</keyword>
  <keyword>Tissue remodelling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

